Tacrolimus dose adjustments after the conversion
Eight patients from the expressor group (28.6%) and seven patients from the non-expressor group (21.9%) required an increase in the dose of extended-release tacrolimus during the stud period. The dose of tacrolimus was decreased in two patients from the expressor group (7.1%) and in three patients from the non-expressor group (9.4%). The frequency of tacrolimus dose adjustment did not differ significantly between the study groups (P = 0.787).